| dc.contributor.author | Aricò, M | |
| dc.contributor.author | Mastrangelo, M | |
| dc.contributor.author | Noia, S.P | |
| dc.contributor.author | Mabusi, M.S | |
| dc.contributor.author | Kalolo, A | |
| dc.contributor.author | Pisani, F | |
| dc.date.accessioned | 2024-06-18T11:42:36Z | |
| dc.date.available | 2024-06-18T11:42:36Z | |
| dc.date.issued | 2023-09-28 | |
| dc.identifier.citation | Aricò M, Mastrangelo M, Di Noia SP, Mabusi MS, Kalolo A, Pisani F. The impact of a newly established specialized pediatric epilepsy center in Tanzania: An observational study. Epilepsy & Behavior. 2023 Nov 1;148:109454. | en_US |
| dc.identifier.uri | http://41.93.38.5:8080/xmlui/handle/123456789/75 | |
| dc.description.abstract | Purpose: This study evaluated the impact of a newly established clinic for the diagnosis of pediatric epilepsy in a resource-limited center (Ifakara, Tanzania). Methods: Patients aged 0–18 years referred to the Pediatric Epilepsy Unit of Saint Francis Referral Hospital were recruited. Demographic and clinical data were collected through Kobo Toolbox and analyzed through a descriptive analysis.. Results: 143 patients were evaluated, and for 48 of them an EEG was recorded (abnormalities were detected in 80.85% of the cases). The diagnosis of epilepsy was confirmed in 87 patients. Focal epilepsy was diagnosed in 57 patients, generalized epilepsy in 24 patients, and forms of unknown onset in 6 patients. Epilepsy was excluded for 9 children. Etiologies included hypoxic-ischemic encephalopathy (39%), central nervous system infections (3.4%), and genetic diseases (3.4%). A specific epilepsy syndrome was diagnosed in 16 patients. 74 patients were under treatment; the most used antiseizure medication (ASM) was phenobarbital (43.36%), followed by carbamazepine (16.08%), sodium valproate (11.19%), phenytoin (2.8%), and lamotrigine (0.7%). Therapeutic changes were proposed to 95 patients, more frequently consisting of withdrawing phenobarbital (39.16%), switching to sodium valproate (27.97%), switching to or adjusting carbamazepine dosage (27.27%), and starting prednisone (2.8%). 76% of the patients with confirmed epilepsy achieved complete seizure freedom at the fourth follow-up consultation. Conclusions: Our data depicted the epilepsy spectrum and highlighted the prognostic implications of improving the availability of ASMs such as sodium valproate and second- and third-generation ones in resource-limited countries. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier Inc. | en_US |
| dc.relation.ispartofseries | Epilepsy & Behavior; | |
| dc.subject | Seizures; | en_US |
| dc.subject | Electroencephalography (EEG); | en_US |
| dc.subject | Antiseizure medications (ASMs); | en_US |
| dc.subject | Epilepsy treatment gap (ETG); | en_US |
| dc.subject | Children. | en_US |
| dc.title | The impact of a newly established specialized pediatric epilepsy center in Tanzania: An observational study | en_US |
| dc.type | Article | en_US |